GlobalData on MSN1d
Boehringer and partners commence gene therapy trial for cystic fibrosis
Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...
precisionmedicineonline2d
Boehringer Ingelheim Kicks Off Inhaled Cystic Fibrosis Gene Therapy Phase I/II Trial With Partners
Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.
Oxford Biomedica to support Boehringer Ingelheim’s LENTICLAIR 1 trial
OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...
pharmaphorum2d
Boehringer eyes third quarter FDA verdict for oral HER2 drug
AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...
PharmiWeb2d
Boehringer’s zongertinib receives Priority Review…
Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...
FDA grants priority review for Boehringer’s zongertinib NDA in NSCLC
The US Food and Drug Administration (FDA) has granted priority review to Boehringer Ingelheim’s new drug application (NDA) ...
Daily2d
Boehringer Ingelheim gets USFDA priority review for Zongertinib for HER2 (ERBB2)-mutant advanced non-small cell lung cancer treatment
Ingelheim: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to ...
precisionmedicineonline3d
FDA Accepts Boehringer Ingelheim's New Drug Application for HER2-Targeted Therapy in NSCLC
In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.
Targeted Oncology3d
FDA Grants Priority Review to Zongertinib in HER2-Mutant NSCLC
Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...
emjreviews.com3d
FDA fast-tracks Boehringer’s NSCLC drug review
The FDA has granted Priority Review to Boehringer Ingelheim's new drug application for its non-small cell lung cancer therapy ...
Monthly Prescribing Reference3d
Zongertinib Under Review for HER2-Mutant Advanced NSCLC
The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...